I learned a lot of things during the three decades I've spent watching, chronicling and digging deep into the machinations of the world's public companies.
And one of the key lessons I learned was also one of the most powerful when it comes to making money.
The lesson: When troubled companies make serious upgrades in their executive ranks, big upgrades in the business - and the firm's stock price - usually follow.
And one of our newest biotech recommendations - which has already made two big changes in its "C-Suite" ranks - just made another bold move.
This is premium content for Private Briefing subscribers only.